Wells Pharma OF Houston LLC: FDA regulatory signals
This page aggregates the United States FDA regulatory records that reference Wells Pharma OF Houston LLC in the datasets indexed by this site. Across the ingested data, Wells Pharma OF Houston LLC is associated with 7 recall record(s), 0 drug-shortage record(s), and 0 approval record(s). The most recent dated event attributed to this firm in the indexed data is a recall record dated 2026-05-06. These counts are coverage-limited activity signals derived only from the specific FDA datasets indexed here. They are NOT quality ratings, reputational scores, or judgements about the firm or its products. A higher or lower count reflects how often a firm appears in these particular public records over the ingested window — nothing more. Recalls and shortages are routine parts of pharmaceutical regulation, and their presence here is an administrative fact, not an indication of wrongdoing or of product danger. Use this page as a finding aid to locate the underlying FDA records, then verify every detail against the official source. This page contains regulatory information only and offers no medical advice.
Signal summary
| Recall records | 7 |
|---|---|
| Shortage records | 0 |
| Approval records | 0 |
| Most recent record date | 2026-05-06 |
| Most recent record type | recall |
These counts are not a quality rating. They are coverage-limited activity signals showing how often this firm appears in the indexed FDA recall and shortage records over the ingested window. They are not reputational scores or judgements about the firm or its products.
Recall records
- Ketamine Hydrochloride Injectable Solution, 50mg/ml, (50 mg per mL) Volume: 1 mL, 5265 Kitty Drive, Houston, TX 77054, NDC 73702-302-31. · Class II · 2026-05-06
- fentaNYL Citrate Injectable Solution in 0.9% Sodium Chloride, 1000 mcg/50mL (20 mcg per mL), well pharma of Houston, NDC 73702-203-65. · Class II · 2026-05-06
- fentaNYL Citrate injectable Solution in 0.9% Sodium Chloride, Narcotic, (2500 mcg/ 250 mL) (10 mcg per mL), 250 mL bag, wells pharma of Houston, NDC 73702-202-03. · Class II · 2026-05-06
- fentaNYL Citrate Injectable Solution, NARCOTIC, Cii, 1000 mcg/100 mL (10 mcg per mL), 100 mL bag, Wells Pharma in Houston, NDC 73702-202-02. · Class II · 2026-05-06
- fentaNYL Citrate Injectable Solution, Narcotic, CII, 1250 mcg/25mL (50 mcg per mL), 25 mL, wells pharma of Houston, NDC 73702-204-25. · Class II · 2026-05-06
- Phenylephrine Hydrochloride Injectable Solution, 40mg, 250*mL Bag, wells pharma of Houston, NDC 73702-122-03 · Class II · 2026-05-06
- fentaNYL Citrate Injectable Solution in 0.9% Sodium Chloride, 50 mcg/5mL)(10 mcg per mL), wells pharma, NDC 73702-202-15. · Class II · 2026-05-06
Source limitations
This page is built only from the FDA recall and shortage records this site has ingested. It does not represent the firm's full regulatory history, its approvals, or any data held in sources not indexed here. The ingested window is finite and can lag the live FDA record, so counts and dates reflect a point in time. Every linked record points back to the verifiable official source; confirm details there. This page contains regulatory information only and offers no medical advice, no assessment of product safety, and no recommendation of any kind.
Source & provenance
- Official source
- https://open.fda.gov/apis/drug/enforcement/
- Source dataset
- openFDA (enforcement + shortages)
- Publication date
- Not available
- Ingested
- 2026-06-09
Verify every value against the official FDA source above. This site links to the regulator's record rather than replacing it.